Drug Target Review

MARCH 4, 2025

Obesity treatment is undergoing a major shift, much like the advances seen in cancer care. Phenomix Sciences , led by CEO Mark Bagnall, is using precision medicine to make treatments more targeted and effective. Phenomix Sciences, built on over a decade of clinical research at the Mayo Clinic, is disrupting this outdated approach.

Therapies 52

Therapies Treatment Clinical Trials Science 52

Drug Patent Watch

MARCH 18, 2025

One company that stands out is R-Pharm, a leading Russian pharmaceutical company that has been at the forefront of innovation in the country. Another notable player is Pharmstandard, a Russian pharmaceutical company that has been a pioneer in the development of innovative medicines.

Biosimilars 92

Biosimilars Pharmaceutical Companies Government Pharmaceuticals 92

Drug Patent Watch

DECEMBER 9, 2024

This includes: Preclinical studies Clinical trials Regulatory approval Manufacturing and marketing Throughout this process, pharmaceutical companies seek to protect their investments through patents.

Drugs 94

Drugs Drug Development Pharmaceuticals Production 94

Drug Target Review

AUGUST 6, 2024

Autoimmune diseases : Rheumatoid Arthritis : ADCs targeting specific immune cells or inflammatory mediators can provide more precise treatment options with potentially fewer side effects. Obesity : By targeting adipose tissue or specific metabolic pathways, ADCs could offer new treatments for obesity and related metabolic disorders.

Therapies 120

Therapies Pharmaceutical Companies Disease Treatment 120

The Pharma Data

JUNE 25, 2025

Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.

RNA 52

RNA Clinical Trials Disease Small Molecule 52

Drug Patent Watch

MARCH 10, 2025

A world where patients have access to life-saving medications sooner, and pharmaceutical companies can bring new treatments to market faster. Will we see a surge in new treatments and medications? Imagine a world where generic drugs can be developed and approved in a fraction of the time it takes today.

Drug Development 52

Drug Development Pharmaceutical Companies Drugs Pharmaceuticals 52

DrugBank

MARCH 7, 2024

Inspired by its success, pharmaceutical companies are pursuing the development of drugs with similar therapeutic profiles, aiming to expand treatment options. Key Players and Challenges For pharmaceutical giants like Novo Nordisk and Eli Lilly, 2024 presents both opportunities and challenges.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Clinical Trials Therapies 98

The Pharma Data

JUNE 18, 2025

Metastatic castration-resistant prostate cancer represents the most advanced and lethal form of the disease, defined by progression despite androgen deprivation therapy and subsequent ARPI treatment. This has created an urgent need for more effective and tolerable treatments for this population.

Trials 40

Trials Therapies Clinical Trials Treatment 40

The Pharma Data

JULY 3, 2025

NASDAQ: SBFM), a pharmaceutical company focused on developing and commercializing life-saving medicines across oncology, antiviral therapies, and other therapeutic areas, has announced the commercial launch of its first biosimilar drug, NIOPEG® , in Canada.

Marketing 52

Marketing Biosimilars Pharmaceutical Companies Pharmaceuticals 52

DrugBank

MARCH 15, 2024

The weight loss industry has emerged as a major hub for innovative research, groundbreaking treatments, and economic opportunity.   Mounjaro received approval as a treatment for diabetes in 2022, then in late 2023, under the brand name Zepbound (tirzepatide), it was approved for weight loss. With sales soaring to $2.2

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceuticals Treatment Clinical Trials 97

The Pharma Data

JUNE 24, 2025

We are proud that our partnership with Tsinghua University has set a benchmark for scientific research collaboration between multinational pharmaceutical companies and high-profile academic institutions in China.

Pharma R&D 40

Pharma R&D Pharmaceutical Companies Pharmaceuticals Science 40

Drug Patent Watch

MARCH 13, 2025

From manufacturing and quality control to distribution and regulatory compliance, the stakes are high for pharmaceutical companies looking to bring these life-changing treatments to market. Key Takeaways: Biosimilar manufacturers must navigate complex supply chain challenges to bring life-changing treatments to market.

Biosimilars 52

Biosimilars Production Compliance Pharmaceutical Companies 52

The Pharma Data

DECEMBER 17, 2020

18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

Drug Target Review

JULY 3, 2025

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. This is especially relevant with today’s heavier focus on enhancing personalised medicine via broader emerging scientific findings.

Drug Development 65

Drug Development Drugs Animal Testing Engineering 65

Drug Patent Watch

DECEMBER 18, 2024

Consider using a variety of claim types, including: Compound claims Method of treatment claims Formulation claims Dosage regimen claims Each type of claim offers different protections and can be valuable in different scenarios. Method claims related to diagnostic tests and personalized treatment regimens are becoming increasingly important.

Pharmaceuticals 96

Pharmaceuticals Drugs Drug Development Marketing 96

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Drug Patent Watch

MARCH 18, 2025

In emerging markets, where healthcare budgets are often stretched thin, generics have been a lifeline for patients who might otherwise go without the treatments they need. By investing in generic drug development, pharmaceutical companies can tap into this lucrative market and make a real difference in the lives of millions.

Drug Development 52

Drug Development Marketing Pharmaceutical Companies Drugs 52

SugarCone Biotech

JUNE 27, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. Each target and each therapeutic modality induces varying degrees of clinical efficacy, as well as causing toxicities.

Therapies 64

Therapies Pharmaceutical Companies Trials Regulations 64

Broad Institute

DECEMBER 18, 2023

Brain disorders are difficult to study and many drug candidates have failed in clinical trials, causing pharmaceutical companies to reduce their investments or even exit the field entirely. But a new path for bringing treatments to patients is starting to emerge. We all recognize the vast, unmet medical need.

Drug Development 130

Drug Development Clinical Trials Drugs Disease 130

Drug Target Review

MARCH 3, 2025

The search for effective treatments for neurodegenerative diseases like Parkinson’s disease has long been hindered by the brain’s complexity and the absence of adequate models for drug discovery. This approach has the potential to revolutionise clinical trial design and lead to more effective, personalised treatments.

Disease 52

Disease Treatment Cell Biology Research 52

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. “We

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

MARCH 26, 2021

Despite continuous innovations in the treatment landscape, unmet needs remain. Overall, the number of treatment-emergent adverse events reported was similar between the ponesimod and teriflunomide treated groups, and the majority were mild/moderate and did not warrant treatment discontinuation. vs. 9.4%), nasopharyngitis (19.3%

Treatment 52

Treatment Pharmaceutical Companies Pharmaceuticals FDA Approval 52

The Pharma Data

MARCH 7, 2022

Astellas”) today announced topline results from the Phase 3 SKYLIGHT 4™ clinical trial investigating the long-term safety of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS) which will support future regulatory filing submissions.

Treatment 52

Treatment Clinical Trials Trials Pharmaceutical Companies 52

Drug Target Review

JANUARY 8, 2024

Our lead program utilises OSK for the treatment of age-related optic neuropathies. a commercial stage pharmaceutical company. a clinical-stage private biopharma company developing therapies for neurological and psychiatric diseases. What evidence is there that we can reverse aging with drugs?

Science 145

Science Disease FDA Approval Pharmaceutical Companies 145

The Pharma Data

JUNE 6, 2025

The Strategic Role of CSOs in a Changing Pharmaceutical Landscape Pharmaceutical contract sales outsourcing is no longer viewed as a temporary or stop-gap measure. Equally important is regulatory compliance. Today’s CSOs are expected to adhere to frameworks like HIPAA , GDPR , the Sunshine Act , and regional promotional codes.

Pharmaceutical Companies 40

Pharmaceutical Companies Compliance Pharmaceuticals International 40

The Pharma Data

AUGUST 19, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

DrugBank

SEPTEMBER 19, 2024

Oral drug delivery remains the gold standard in pharmaceutical administration. It offers convenience for patients, promotes medication adherence, and improves treatment outcomes. This could aid in treatment for diabetic patients who currently rely on injections. This knowledge is instrumental in optimizing treatment plans.

Drugs 98

Drugs Pharmacokinetics Treatment Disease 98

Drug Patent Watch

JANUARY 14, 2025

The stakes are higher than ever, with billions of dollars and potentially life-saving treatments on the line. Key Stakeholders in Pharmaceutical Negotiations Successful negotiations in the pharmaceutical industry require a deep understanding of the various stakeholders involved.

Pharmaceuticals 54

Pharmaceuticals Compliance Licensing Licensing 54

The Pharma Data

MARCH 13, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for lanadelumab subcutaneous injection, a monoclonal antibody therapy for prophylaxis against attacks of hereditary angioedema (HAE).

Treatment 52

Treatment Pharmacokinetics Drugs Production 52

H1 Blog

JULY 24, 2023

How do pharmaceutical companies work with payers? In this blog post, we’ll take a closer look at how payer trends can reveal insights into the way patients use their medications – and how pharmaceutical companies can use this data to help improve patient outcomes.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Pharmacy 52

H1 Blog

DECEMBER 4, 2023

As the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. With the rise of digital health and data, there are endless possibilities for reaching vulnerable populations and improving access to treatment.

Clinical Trials 59

Clinical Trials Trials Pharmaceutical Companies Drug Development 59

Antidote

JANUARY 3, 2024

While the primary goal of clinical trials is to help identify potential new treatments that improve people's health and save lives, it's the unfortunate truth that the patient experience is often not prioritized.

Clinical Trials 52

Clinical Trials Trials Pharmaceutical Companies Pharmaceuticals 52

The Pharma Data

AUGUST 17, 2020

This deal means the French pharmaceutical company will take full control of Principa, which includes its development of treatments for multiple sclerosis and a range of other autoimmune disorders. Sanofi is attempting to grow its pipeline of BTK inhibitors to rejuvenate the company by focusing on high priced medicines.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Trials 52

Altus Drug Development

JUNE 30, 2022

While this strategy is widely adopted by modern pharmaceutical companies, in recent years, its effectiveness has begun to wane. This novel approach promises to create great advantages for the pharmaceutical companies who adopt it and might become the future of medicine.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Production 52

Drug Patent Watch

JANUARY 14, 2025

The FDA’s Response: A Real-World Study In response, the FDA sponsored a study that examined over 15,000 patients undergoing levothyroxine treatment[2]. The Plot: Generic vs. Brand-Name Two major pharmaceutical companies sued over 10 generic drug manufacturers for infringing on a patent for their schizophrenia medication[4].

Drug Development 71

Drug Development Drugs FDA Production 71

DrugBank

JUNE 27, 2024

Opportunities in Drug Repurposing There is great potential for drug repurposing to unlock treatments for rare and neglected diseases, where traditional drug development is too costly. Pharma companies are often rich with valuable chemical libraries and expertise, while academics bring emerging disease biology knowledge.

Drugs 98

Drugs Pharma Companies Clinical Trials Computational Chemistry 98

Drug Target Review

JUNE 2, 2025

Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments.

Small Molecule 52

Small Molecule Engineering Therapies Drugs 52